Camrelizumab Combined With Liposomal Doxorubicin and Losartan in the Treatment With Advanced or Locally Advanced Triple-negative Breast Cancer Who Have Received no More Than 1 Prior Line of Chemotherapy
Latest Information Update: 01 Nov 2021
At a glance
- Drugs Camrelizumab (Primary) ; Doxorubicin (Primary) ; Losartan (Primary)
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 01 Nov 2021 New trial record